Patent Application
20180245125
The present invention relates to a platform technology for evaluating the antimicrobial activity of a known antibiotic against specified resistance mechanisms and also for screening for new antimicrobial agents.
The emergence of antibiotic resistance has become a major clinical and public health threat worldwide.1.2 According to a recent report from the United Kingdom, if antimicrobial resistance continues to increase, 10 million people will die due to it annually by 2050, a mortality rate greater than that of cancer.1 Correct use of antibiotics and the development of novel antibiotics are both necessary to overcome this crisis.
World Health Organization (WHO) reported an extremely high resistant rates in Klebsiella pneumoniae, Escherichia coli and Staphylococcus aureus, which are common causes of hospital and community infections.4 K. pneumoniae and E. coli both belong to Enterobacteriaceae and have similar antibiotic resistance mechanisms.5 Understanding the antibiotic effectiveness against each resistant mechanism can help us to develop and use antibiotics. Traditionally, a large number of clinical drug-resistance isolates are collected and used for testing and screening antibiotics before going into clinical trials.6 However, the resistance mechanisms in clinical isolates usually are complex and not fully identified. It is difficult to verify which mechanism is actually involved or plays the major role in conferring the drug resistance. Without the certain information, it is also difficult to modify the antibiotic candidates for improving its antimicrobial activity in an efficient manner.
The present design provides a platform technology for testing, screening, selecting and evaluating antibiotics by using genetically engineered strains with identified, individual or combined, resistance mechanisms, prepared from a multidrug (or preferably fully) susceptible clinical isolate.
Specifically, the present invention provides a platform technology for screening for antimicrobial agents by using genetic engineering bacterial strains, wherein these bacterial strains before genetic engineering are in nature highly susceptible to antibiotic treatment (preferably susceptible to multiple antibiotic treatment) and after genetic engineering it is given one or more mutations or antibiotic resistance genes based on the major types of drug-resistant mechanisms, selected form the group consisting of (i) decrease antibiotic permeability by loss of outer membrane proteins, (ii) pump out the antibiotics by overexpression of efflux pumps, (iii) eliminates or reduces binding of antibiotic by modification of antibiotic target or by acquirement of antibiotic-resistant target, and (iv) inactivate antibiotic by enzymatic cleavage or modification, and any combinations thereof. Since the drug-resistant mechanism given in the genetic engineering bacterial strains is known and identified, once an agent is cultured with the genetic engineering bacterial strain and determined to have an antimicrobial activity against it, we can thus figure out that the agent is specifically active against the drug-resistant mechanism given in the genetic engineering bacterial strains. Accordingly, the platform technology of the invention is feasible and efficient to identify an antimicrobial agent targeting a particular drug-resistant mechanism as desired. In addition, the platform technology of the invention, as compared with a conventional screening method using clinical resistant isolates, is less labor intensive and also is workable for carrying out a large-scale screening for an antimicrobial agent, especially for an antimicrobial agent active against multiple drug-resistant mechanisms, and moreover is meaningful to apply the selected antimicrobial agent to subsequent drug modification.
In particular, the present invention provides a method for screening for an antimicrobial agent, comprising:
(1) providing a wild-type (WT) susceptible bacterial strain which has a WT-referenced resistance level to a reference antibiotic;
(2) providing a first genetic engineering bacterial strain generated from the WT susceptible bacterial strain which is given a first mutation or antibiotic resistance gene (ET1) via a genetic engineering manner to confer drug resistance to the reference antibiotic, exhibiting a ET1-referenced resistance level to the reference antibiotic, wherein the ET1-referenced resistance level is higher than the WT-referenced resistance level;
(3) culturing the wild-type susceptible bacterial strain in the presence of a first test agent and analyzing the first test agent for its activity against the wild-type susceptible bacterial strain to obtain a WT-Test1 resistance level;
(4) culturing the first engineered bacterial strain in the presence of the first test agent and analyzing the first test agent for its activity against the first engineered bacterial strain to obtain a ET1-Test1 resistance level;
(5) obtaining a ET1-Test1 ratio of the ET1-Test1 resistance level to the WT-Test1 resistance level; and
(6) determining if the first test agent is a potentially effective antimicrobial agent against the drug resistance associated with ET1 in the first engineered bacterial strain based on the ET1-Test1 ratio.
In some embodiments, the ET1-referenced resistance level is higher than the WT-referenced resistance level by 1-fold, 2-fold, 3-fold, or 4-fold or more.
In some embodiments, the wild-type susceptible bacterial strain is susceptible to multiple antibiotics, selected from the group consisting of β-lactams, quinolones, aminoglycosides, tetracyclines, folate pathway inhibitors, polymyxins, phenicols, fosomycins, nitrofurans and any combinations thereof.
In some embodiments, the first test agent is determined as a potentially effective antimicrobial agent against the drug resistance associated with ET1 if the ET1-Test1 ratio is no more than 4 (e.g. 4 or less, 3 or less, 2 or less, 1 or less).
In more particular, the method of the invention further comprises:
(7) (17) culturing the wild-type susceptible strain in the presence of a second test agent and analyzing the second test agent for its activity against the wild-type susceptible strain to obtain a WT-Test2 resistance level;
(8) (18) culturing the first engineered bacterial strain in the presence of the second test agent and analyzing the second test agent for its activity against the first engineered bacterial strain to obtain a ET1-Test2 resistance level;
(9) (19) obtaining a ET1-Test2 ratio of the ET1-Test2 resistance level to the WT-Test2 resistance level; and
(10) (20) determining if the second test agent is a potentially effective antimicrobial agent against the drug resistance associated with ET1 in the first engineered bacterial strain based on the ET1-Test2 ratio.
In some embodiments, the second test agent is determined as a potentially effective antimicrobial agent against the drug resistance associated with ET1 if the ET1-Test2 ratio is no more than 4 (e.g. 4 or less, 3 or less, 2 or less, 1 or less).
In some embodiments, the second test agent is determined as a potentially effective antimicrobial agent against the drug resistance associated with ET1 if the ET1-Test2 resistance level, which is expressed by minimum inhibitory concentration (MIC), is no more than 10 μg/ml, 5 μg/ml, 2.5 μg/ml, 1 μg/ml or 0.5 μg/ml.
In more particular, the method of the invention further comprises:
(11) ranking the first test agent and the second test agent for a preferable antimicrobial activity according to the ET1-Test1 ratio and the ET1-Test2 ratio, the lower the ratio, the higher the ranking.
In more particular, the method of the invention further comprises:
(12) providing a second engineered bacterial strain generated from the WT susceptible bacterial strain which is given a second mutation or antibiotic resistance gene (ET2) in a genetic engineering manner to confer drug resistance to the reference antibiotic, exhibiting a ET2-referenced resistance level to the reference antibiotic, wherein the ET2-referenced resistance level is higher than the WT-referenced resistance level;
(13) culturing the second engineered bacterial strain in the presence of the first test agent and analyzing the first test agent for its activity against the second engineered bacterial strain to obtain a ET2-Test1 resistance level;
(14) obtaining a ET2-Test1 ratio of the ET2-Test1 resistance level to the WT-Test1 resistance level;
(15) determining if the first test agent is a potentially effective antimicrobial agent against the drug resistance associated with ET2 in the second engineered bacterial strain based on the ET2-Test1 ratio.
In some embodiments, the first test agent is determined as a potentially effective antimicrobial agent against the drug resistance associated with ET2 if the ET2-Test1 ratio is no more than 4 (e.g. 4 or less, 3 or less, 2 or less, 1 or less).
In some embodiments, the first test agent is determined as a potentially effective antimicrobial agent against the drug resistance associated with ET2 if the ET2-Test1 resistance level, which is expressed by minimum inhibitory concentration (MIC), is no more than 10 μg/ml, 5 μg/ml, 2.5 μg/ml, 1 μg/ml or 0.5 μg/ml.
In more particular, the method of the invention further comprises: (16) obtaining a first sum ratio value with respect to the first test agent by adding the ET1-Test1 ratio to the ET2-Test1 ratio.
In more particular, the method of the invention further comprises:
(17) culturing the wild-type susceptible strain in the presence of a second test agent and analyzing the second test agent for its activity against the wild-type susceptible strain to obtain a WT-Test2 resistance level;
(18) culturing the first genetic engineering bacterial strain in the presence of the second test agent and analyzing the second test agent for its activity against the first genetic engineering bacterial strain to obtain a ET1-Test2 resistance level;
(19) obtaining a ET1-Test2 ratio of the ET1-Test2 resistance level to the WT-Test2 resistance level; and
(20) determining if the second test agent is a potentially effective antimicrobial agent against the drug resistance associated with ET1 in the first genetic engineering bacterial strain based on the ET1-Test2 ratio.
In some embodiments, the second test agent is determined as a potentially effective antimicrobial agent against the drug resistance associated with ET1 if the ET1-Test2 ratio is no more than 4 (e.g. 4 or less, 3 or less, 2 or less, 1 or less).
In some embodiments, the second test agent is determined as a potentially effective antimicrobial agent against the drug resistance associated with ET1 if the ET1-Test2 resistance level, which is expressed by minimum inhibitory concentration (MIC), is no more than 10 μg/ml, 5 μg/ml, 2.5 μg/ml, 1 μg/ml or 0.5 μg/ml.
In more particular, the method of the invention further comprises:
(21) culturing the second engineered bacterial strain in the presence of the second test agent and analyzing the second test agent for its activity against the second engineered bacterial strain to obtain a ET2-Test2 resistance level;
(22) obtaining a ET2-Test2 ratio of the ET2-Test2 resistance level to the WT-Test2 resistance level;
(23) determining if the second test agent is a potentially effective antimicrobial agent against the drug resistance associated with ET2 in the second engineered bacterial strain based on the ET2-Test2 ratio.
In some embodiments, the second test agent is determined as a potentially effective antimicrobial agent against the drug resistance associated with ET2 if the ET2-Test2 ratio is no more than 4 (e.g. 4 or less, 3 or less, 2 or less, 1 or less).
In some embodiments, the second test agent is determined as a potentially effective antimicrobial agent against the drug resistance associated with ET2 if the ET2-Test2 resistance level, which is expressed by minimum inhibitory concentration (MIC), is no more than 10 μg/ml, 5 μg/ml, 2.5 μg/ml, 1 μg/ml or 0.5 μg/ml.
In more particular, the method of the invention further comprises: (24) obtaining a second sum ratio value with respect to the second test agent by adding the ET1-Test2 ratio to the ET2-Test2 ratio.
In more particular, the method of the invention further comprises: (25) ranking the first test agent and the second test agent for a preferable antimicrobial activity according to the first sum ratio value and the second sum ratio value, the lower the value, the higher the ranking.
In more particular, the method of the invention further comprises: (26) ranking the first test agent and the second test agent for a preferable antimicrobial activity according to the ET2-Test1 ratio and the ET2-Test2 ratio, the lower the ratio, the higher the ranking.
In some embodiments, the preferable antimicrobial activity includes an antimicrobial activity against multiple drug-resistance mechanisms.
In some embodiments, the first mutation or antibiotic resistance gene, or the second mutation or antibiotic resistance gene is given based on one or more drug-resistant mechanisms selected form the group consisting of (i) decrease antibiotic permeability by loss of outer membrane proteins, (ii) pump out the antibiotics by overexpression of efflux pumps, (iii) eliminates or reduces binding of antibiotic by modification of antibiotic target or by acquirement of antibiotic-resistant target, and (iv) inactivate antibiotic by enzymatic cleavage or modification, and any combinations thereof.
In some embodiments, the first mutation or antibiotic resistance gene, or the second mutation or antibiotic resistance gene is selected from the group consisting of: ΔompK35, ΔompK36, ΔramR, GyrA S83I, GyrA S83L, GyrA S83F, GyrA S83Y, GyrA D87N, ParC S801, CTX-M-14, CTX-M-15, SHV-12, CMY-2, DHA-1-AmpR, KPC-2, KPC-3, IMP-8, NDM-1, VIM-1, OXA-48, QnrB, QnrS, AAC(6′)-Ib-cr, AAC(6′)-Ib-cr, AAC(3)-IId, AAC(3)-IVa, ANT(2″)-Ia, ANT(3″)-Ia, APH(3′)-Ia, APH(3′)-IIa, StrA-StrB, ArmA, RmtB, Tet(A), Tet(B), Tet(C), Tet(D), Tet(M), Sul1, Sul2, DfrA1, DfrA16, AdeR D20N, AdeR A91V, AdeR P116L, AdeS G30D, AdeS A94V, AdeS R152K, AdeS T153M, ParC G78C, ParC S80L, ParC S80W, ParC S80Y, ParC E84K, VEB-3, ADC-30, IMP-1, OXA-23, OXA-58, OXA-66, OXA-72, AAC(3)-IIa, APH(3′)-VIa, and any combinations thereof.
In some embodiments, the first mutation or antibiotic resistance gene, or the second mutation or antibiotic resistance gene is given by a chromosome-mediated approach or a plasmid-mediated approach.
The foregoing summary, as well as the following detailed description of the invention, will be better understood when read in conjunction with the appended drawings. For the purpose of illustrating the invention, there are shown in the drawings embodiments which are presently preferred. It should be understood, however, that the invention is not limited to the precise arrangements and instrumentalities shown.
In the drawings:
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by a person skilled in the art to which this invention belongs.
As used herein, the singular forms “a”, “an”, and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to “a sample” includes a plurality of such samples and equivalents thereof known to those skilled in the art.
As used herein, the term “drug resistance” can refer to a cell's increasing resistance to drug treatment, such as antibiotic treatment.
As used herein, the terms “susceptible” and “antibiotic susceptibility” can indicate that the growth of a microorganism is inhibited by a normal achievable concentration of an antimicrobial agent when the recommended dosage is used.
As used herein, the terms “resistant” and “antibiotic resistance” can indicate that microorganism growth is not inhibited by a normal achievable concentration of the agent and clinical efficacy of the agent against the microorganism has not been shown in treatment studies.
As used herein, a resistance level with reference to a bacterial strain for a particular agent can indicate a minimal amount of the particular agent that will inhibit the visible growth of a microorganism, such as a minimum inhibitory concentration (MIC). A bacterial strain with a lower resistance level to an agent can indicate that the bacterial strain is relatively susceptible to the agent (reflecting a relatively lower MIC), while a bacterial strain with a higher resistance level to an agent can indicate that the bacterial strain is relatively resistant to the agent (reflecting a relatively higher MIC).
According to the present invention, a bacterial strain can be from any bacterial species, particularly a species leading to common infectious diseases in human, including but not limited to, Gram-negative bacteria, such as K. pneumonia, Escherichia coli, Salmonella spp., Acinetobacter baumannii and Pseudomonas aeruginosa, and Gram-positive bacteria, such as Staphylococcus aureus and Enterococcus spp.
As used herein, a wild-type susceptible bacterial strain can indicate a bacterial strain, the genome of which is not modified by a genetic engineering manner and which is susceptible to antibiotic treatment. Preferably, a wild-type susceptible bacterial strain as used herein is susceptible to multiple antibiotics, selected from the group consisting of β-lactams, quinolones, aminoglycosides, tetracyclines, folate pathway inhibitors, polymyxins, phenicols, fosomycins, nitrofurans and any combinations thereof. A particular example of a wild-type susceptible bacterial strain as used herein includes K. pneumoniae strain NVT1001, which can be obtained for example from Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, Taipei 114, Taiwan.
As used herein, a genetically engineered bacterial strain can be generated from a wild-type susceptible bacterial strain via a genetic engineering manner, which after the genetic engineering, is given mutation or antibiotic resistance gene to confer drug resistance. The genetic engineering can be conducted by a conventional method as known in the art, such as by a chromosome-mediated approach (e.g. mutating a gene in the chromosome of the strain to confer drug resistance) or a plasmid-mediated approach (e.g. adding a foreign gene to confer drug resistance in the strain). The genetically engineered bacterial strain can include one or more genetic changes based on one or more drug-resistant mechanisms selected form the group consisting of (i) decrease antibiotic permeability by loss of outer membrane proteins, (ii) pump out the antibiotics by overexpression of efflux pumps, (iii) eliminates or reduces binding of antibiotic by modification of antibiotic target or by acquirement of antibiotic-resistant target, and (iv) inactivate antibiotic by enzymatic cleavage or modification, and any combinations thereof. In some embodiments, the mutation or antibiotic resistance gene is selected from the group consisting of: ΔompK35, ΔompK36, ΔramR, GyrA S83I, GyrA S83L, GyrA S83F, GyrA S83Y, GyrA D87N, GyrA S80I, CTX-M-14, CTX-M-15, SHV-12, CMY-2, DHA-1-AmpR, KPC-2, KPC-3, IMP-8, NDM-1, VIM-1, OXA-48, QnrB, QnrS, AAC(6′)-Ib-cr, AAC(6′)-Ib-cr, AAC(3)-IId, AAC(3)-IVa, ANT(2″)-Ia, ANT(3″)-Ia, APH(3′)-Ia, APH(3′)-IIa, StrA-StrB, ArmA, RmtB, Tet(A), Tet(B), Tet(C), Tet(D), Tet(M), Sul1, Sul2, DfrA1, DfrA16, AdeR D20N, AdeR A91V, AdeR P116L, AdeS G30D, AdeS A94V, AdeS R152K, AdeS T153M, ParC G78C, ParC S80L, ParC S80W, ParC S80Y, ParC E84K, VEB-3, ADC-30, IMP-1, OXA-23, OXA-58, OXA-66, OXA-72, AAC(3)-IIa, APH(3′)-VIa, and any combinations thereof. In some embodiments, the mutation or antibiotic resistance gene is preferably include genetic changes as many as possible which can be used to screen for a strong antimicrobial agent against multiple drug-resistant mechanisms.
The present invention provides a method for screening for an antibiotic agent. In particular, the method of the invention creates a genetically engineered bacterial strain from a wild-type susceptible bacterial strain via a genetic engineering manner, which after the genetic engineering, is given mutation or antibiotic resistance gene to confer drug resistance to a reference antibiotic based on one or more drug-resistant mechanisms; a test agent is then added to a culture of the wild-type susceptible bacterial strain and a culture of the genetically engineered bacterial strain to analyze for its activity against the wild-type susceptible bacterial strain and the genetically engineered bacterial strain, respectively, wherein the activity of the test agent against the bacterial strains can be expressed by a minimum inhibitory concentration (MIC) (also referring to a resistance level as described herein; typically, a higher MIC indicates a higher resistance level and a lower antimicrobial activity, and a lower MIC indicates a lower resistance level and a higher antimicrobial activity); and if the activity of the test agent against the genetically engineered bacterial strain is similar to that against the wild-type susceptible bacterial strain, the test agent is selected as a potential antimicrobial agent against the same species of the bacterial strain. In general, the antimicrobial activity of a test agent is expressed by MIC, which is preferably no more than 10 μg/ml, 5 μg/ml, 2.5 μg/ml, 1 μg/ml or 0.5 μg/ml.
Table A shows an embodiment of the method of the present invention.
In certain embodiments, the method of the invention is to identify a potential agent with antimicrobial activity against multiple drug-resistance mechanisms.
In particular, the method of the present invention is advantageous to develop a platform technology to screen for a large number of agents for their antimicrobial activity. In addition, once a test agent is determined as a potentially antimicrobial agent in a first run of the process, it can be subjected to a subsequent run of the process by creating another genetically engineered bacterial strain with a new mutation or antibiotic resistance gene and repeating the steps of culturing, obtaining a resistance level and analyzing for its activity against the wild-type susceptible bacterial strain and the genetically engineered bacterial strain. The more times the process is conducted, the more accurate the results, and an agent thus selected by more runs of the process is more effective against various types of drug-resistant mechanisms.
The present invention will now be described more specifically with reference to the following examples, which are provided for the purpose of demonstration rather than limitation.
The system developed in the present study provides a platform technology for testing, screening, selecting and evaluating antibiotics using genetically engineered bacterial strains with individual or combined resistance mechanisms that were constructed from the fully susceptible clinical K. pneumoniae NVT1001 isolate. The chromosome-mediated resistance mechanisms that were constructed in this study are decreased antibiotic permeability, generated by deletion of the genes encoding the outer-membrane proteins OmpK35 and/or OmpK36;7 active antibiotic export, generated by deletion of the ramR regulatory gene, which leads to overexpression of the AcrAB-TolC efflux pump (Tables 1);8-11 and modification of quinolone target sites via gyrA and/or parC mutations.12-15 Most plasmid-mediated mechanisms are specific to one kind of antibiotic group,16 with this study focusing on β-lactams, quinolones, aminoglycosides, tetracyclines and folate pathway inhibitors. Because many kinds of resistance are conferred by combined resistance mechanisms in the clinical setting, mechanisms related to the same antibiotic group were combined. Testing antibiotics against these combined mechanisms can be used to further evaluate their antimicrobial activities.
3.18
3.12
13.37
0
aThe expression of acrAB and tolC is positively regulated by RamA, while RamR is a repressor that regulates ramA expression.1 Previous study has found that after ramR disruption, the expression of acrA, tolC and ramA was increased 3.36-, 3.35- and 25.04-fold respectively,2 while similar results can also obtained in this study.
bBoldface letter indicates at least a 2-fold change compared with that of K. pneumoniae NVT1001 and the results are the mean of three different experiments.
cΔramR, ramR deletion strain of NVT1001; ΔramR::ramR, ramR-complemented strain of ΔramR strain.
In addition, Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa have been identified by the WHO as three critical priority pathogens for the research and development of new antibiotics in 2017.3 Given that the genetic background of A. baumannii is quite different from that of K. pneumoniae, specific resistance genes can be found in this pathogen. Therefore, the strategic system has been constructed by using A. baumannii.
This study includes generation of genetically engineered strains from a fully susceptible clinical isolate of A. baumannii. The chromosome-mediated resistance mechanisms that were constructed in this study are active antibiotic export, generated by mutation of the adeR or adeS regulatory gene, which leads to overexpression of the AdeABC efflux pump;41-46 and modification of quinolone target sites via gyrA and/or parC mutations.47-54 Most plasmid-mediated mechanisms are specific to one kind of antibiotic group,55 with this study focusing on β-lactams, aminoglycosides and tetracyclines. All of these genetically engineered A. baumannii strains are with clear and simple resistance mechanisms and their usability was evaluated via antimicrobial susceptibility testing in this study.
Prior to the present invention, no complete system is available for testing antibiotics against specific resistance mechanisms. This study generated genetically engineered strains with clear and simple resistance mechanisms and evaluated their usability via both in vitro and in vivo assays.
1. Materials and Methods
1.1 Concept and Approach to Engineer the Resistant Strains for Antibiotic Screening System.
To create the bacterial strains for antibiotic screening system, four approaches with different target related antibiotic resistance were used.
For construction of chromosomal mediated resistance, (i) decreasing penetration of antibiotic (knockout outer membrane protein genes ompK35 and ompK36 in K. pneumoniae),7 (ii) increasing the expression of AcrAB-TolC (knockout regulatory gene ramR8-11 or overexpression of the AdeABC efflux pump (mutation of the adeR or adeS regulatory gen)41-46 and (iii) antibiotic target gene mutation were performed.12-15,47-54 For plasmid mediated resistance, different class of plasmid mediated resistant genes including (i) β-lactam resistant genes, (ii) quinolones resistant genes, (iii) aminoglycosides resistant genes, (iv) tetracyclines resistant genes and (v) folate pathway inhibitor resistant genes16 were individually transferred into susceptible strain. See, Tables 2 and 4.
1.2 Bacterial Strains and Plasmids
1.2.1 K. pneumoniae NVT1001
K. pneumoniae NVT1001, capsular serotype 1, is an isolate from a liver-abscess patient in Taiwan17 that was fully susceptible to all antibiotics tested, except ampicillin. The NVT1001 strain was used to construct genetically engineered strains with the antibiotic resistance mechanisms that are shown in Table 2, and the revertants of the NVT1001 mutants constructed in this study are shown in Table 3.
aAmino acid replacements of GyrA or ParC are listed; Resistance genes of plasmid-mediated mechanisms were cloned into the low-copy-number plasmid pACYC177 or pACYC184.
bThe antibiotics listed indicate a significant (≥4-fold) difference in the MICs of the NVT1001 strain and its genetically engineered strains in this study.
1.2.2 A. baumannii KW1
A. baumannii KW1 is a clinical isolate that was fully susceptible to antibiotics tested. The KW1 strain was used to construct genetically engineered strains with the antibiotic resistance mechanisms that are shown in Table 4. The plasmids pYMAb5 and pYMab5Tc are shuttle vectors able to replicate in A. baumannii and Escherichia coli, which carry a resistant determinant of kanamycin or tetracycline respectively. The two shuttle vectors were used to clone the resistance genes of the plasmid-mediated resistance mechanisms in this study (Table 4).
aAmino acid replacement of AdeR, AdeS, GyrA or ParC are listed; resistance genes of plasmid-mediated mechanisms were clone into the shuttle vector pYMAb5 or pYMAb5Tc, which carries a resistant determinant of kanamycin or tetracycline respectively.
bThe antibiotics listed indicate a ≥2-fold difference in the MICs for the KW1 strain and its genetically engineered strains in this study.
1.3 In-Frame Deletion Mutagenesis
The plasmid pUT-kmy, which consists of an R6K origin of replication, an mobRP4 origin of transfer, and a kanamycin resistance cassette,18 was ligated with the sacB gene to generate the plasmid pUT-KB, which was then used to construct the mutants.19 The plasmid pUT-KB is a suicide vector containing the counter-selection marker sacB, which originates from Bacillus subtilis.20 When this gene is expressed via the integrated pUT-KB, it confers a sucrose-susceptibility phenotype, which enables positive selection with sucrose to detect loss of the vector.
Gene deletions in K. pneumoniae strain NVT1001 were constructed via in-frame deletion mutagenesis.7 Briefly, two DNA fragments (approximately 1 kb in size) that flanked the regions to be deleted were amplified by PCR using specific primer pairs. The two gel-purified PCR products, containing complementary ends, were then mixed and amplified via overlap PCR.21,22 The resulting PCR fragment (approximately 2 kb in size) was digested with restriction enzymes and then cloned into pUT-KB that had been similarly digested. For homologous recombination, each of the gene-deletion constructs in pUT-KB was transformed into E. coli S17-1 λpir23 via electroporation and then mobilized into K. pneumoniae strain NVT1001 via conjugation. Single-crossover strains were selected from BIND (Brilliant green containing Inositol-Nitrate-Deoxycholate) plates supplemented with kanamycin (50 mg/L), as the growth of non-K. pneumoniae strains is effectively suppressed on BIND plates.24 After the kanamycin-resistant transconjugants were selected, the insertions of the plasmids were verified via PCR using primer pairs that flanked the target genes. After incubation in 20 mL brain-heart infusion (BHI) broth for 6 hours at 37° C. in the absence of kanamycin, the fully grown cultures were spread onto LB agar plates supplemented with 10% sucrose. After the double crossover occurred, the sucrose-resistant and kanamycin-susceptible colonies were selected, and the gene deletions were confirmed via PCR.
1.4 Site-Directed Mutagenesis
DNA fragments of the entire gyrA and parC sequences along with their flanking regions were amplified from K. pneumoniae strain NVT1001 using PCR with specific primer pairs and then cloned into the plasmid pUT-KB. The QuikChange site-directed mutagenesis kit (Stratagene) was used to generate mutations in the gyrA and parC genes in the plasmid using the methods described by the manufacturer. For homologous recombination, plasmids containing mutations in the gyrA or parC gene were transformed into E. coli S17-1 λpir23 via electroporation and mobilized into K. pneumoniae strain NVT1001 via conjugation. Single-crossover strains were selected from BIND plates supplemented with kanamycin (50 mg/L), as the growth of non-K. pneumoniae contaminants is suppressed on BIND plates.24 After the kanamycin-resistant transconjugants were selected, the insertion of plasmids was verified via PCR. After incubation in 20 mL BHI broth for 6 hours at 37° C. in the absence of kanamycin, the fully grown cultures were spread onto LB agar plates supplemented with 10% sucrose. After the double crossover occurred, the sucrose-resistant and kanamycin-susceptible colonies were selected, and the gene mutations were confirmed via PCR.
Plasmid pUT-kmy, which consists of an R6K origin of replication, a mobRP4 origin of transfer, and a kanamycin resistant determinant,56 was ligated with a sacB gene to generate plasmid pUT-KB for constructing mutants.57 Plasmid pUT-KB is a suicide vector containing a counter-selection marker, sacB, which originates from Bacillus subtilis.58 When this gene is expressed on the integrated pUT-KB, it confers a sucrose-sensitivity phenotype, which enables positive selection with sucrose to detect the loss of the vector.
DNA fragments of the entire adeR, adeS, gyrA and parC along with their flanking regions were amplified from A. baumannii KW1 using PCR with specific primer pairs and then cloned into plasmid pUT-KB. The QuikChange site-directed mutagenesis kit (Stratagene) was used to generate mutations in the adeR, adeS, gyrA and parC genes in the plasmids using the methods described by the manufacturer. For homologous recombination, plasmids containing mutations in the adeR, adeS, gyrA or parC gene were transformed into E. coli S17-1 λpir23 via electroporation and mobilized into A. baumannii KW1 via conjugation. Single-crossover strains were selected from Luria-Bertani (LB) plates supplemented with cefotaxime (1 μg/ml) and kanamycin (50 m/ml), as the growth of non-A. baumannii contaminants is suppressed by cefotaxime (1 μg/ml). The kanamycin-resistant transconjugants were selected and the insertion of plasmids was verified via PCR. After incubation in 20 ml brain heart infusion (BHI) broth for 6 hours in the absence of kanamycin at 37° C., the fully grown cultures were spread onto LB plates supplemented with 10% sucrose. After the double crossover occurred, the sucrose-resistant and kanamycin-susceptible colonies were selected, and the gene mutations were confirmed via PCR.
1.5 Construction of Revertants
The allelic-exchange method was used to restore the wild-type gene in the K. pneumoniae NVT1001 mutants with constructed chromosome-mediated resistance mechanisms, as described by Tsai et al.19 Briefly, a DNA fragment of the entire wild-type gene sequence along with flanking regions was amplified from K. pneumoniae NVT1001 using PCR with specific primers. The resulting PCR fragment was digested and then cloned into pUT-KB. For homologous recombination, this plasmid was transformed into E. coli S17-1 λpir23 via electroporation and mobilized into the K. pneumoniae NVT1001 mutant via conjugation. Single-crossover strains were selected from BIND plates supplemented with kanamycin (50 mg/L), as the growth of non-K. pneumoniae strains is effectively suppressed on the BIND plates.24 After the kanamycin-resistant transconjugants were selected, the insertion of the plasmid was verified via PCR. After incubation in 20 mL BHI broth for 6 hours at 37° C. in the absence of kanamycin, the fully grown cultures were spread onto LB agar plates supplemented with 10% sucrose. After the double crossover occurred, the sucrose-resistant and kanamycin-susceptible colonies were selected, and the restoration of the wild-type gene was confirmed via DNA sequencing.
1.6 Plasmid Construction and Transformation
DNA fragments of the resistance genes along with their flanking regions were amplified from clinical plasmids via PCR with specific primer pairs. The resulting PCR fragments were digested and then cloned into the plasmid pACYC177 or pACYC184. The resulting plasmids were then transformed into K. pneumoniae strain NVT1001 via electroporation. The recombinant bacteria were plated onto LB agar plates containing kanamycin (50 mg/L) or chloramphenicol (50 mg/L), and the presence of the cloned gene was confirmed via PCR and DNA sequencing.
DNA fragments of the resistance genes along with their flanking regions were amplified from clinical plasmids via PCR with specific primer pairs. The resulting PCR fragments were digested and then cloned into the plasmid pYMAb5 or pYMAb5Tc. The resulting plasmids were then transformed into A. baumannii KW1 via electroporation. The recombinant bacteria were plated onto LB agar plates containing kanamycin (50 μg/ml) or tetracycline (50 μg/ml), and the presence of the cloned gene was confirmed via PCR and DNA sequencing.
1.7 Antimicrobial Susceptibility Testing
The MICs of antibiotics were determined using the Etest (Biodisk AB, Sweden) according to the manufacturer's instructions. The MICs from the Etest, which fall between standard two-fold dilutions, were rounded up to the next highest two-fold value. The MICs of ceftazidime and cefotaxime against K. pneumoniae NVT1001 harbouring the pACYC177 plasmid with blaOXA-48 were further determined using a broth microdilution test according to the recommendations of the CLSI,25 and the results were interpreted according to the breakpoints established by the CLSI in 2017.25 Meanwhile, due to the lack of CLSI breakpoints in 2016 and 2017, the results for cephalothin were interpreted according to the breakpoints established by the CLSI in 2015,26 and the results for moxifloxacin were interpreted according to the breakpoints established by the EUCAST in 2017.27
1.8 Mouse Infection Model
Pathogen-free 6- to 8-week-old male BALB/c mice were obtained from the National Laboratory Animal Center (Taiwan) and maintained in the pathogen-free vivarium of the Laboratory Animal Center of National Defense Medical Center (Taiwan). K. pneumoniae NVT1001 harbouring the pACYC177 plasmid with blaOXA-48 was cultured overnight at 37° C. in BHI broth and then diluted (1:100) in fresh BHI broth. The culture was incubated until the mid-exponential growth phase, and the cells were then washed once, resuspended in 0.85% sterile saline, and adjusted to the desired concentrations according to the OD600 value. The concentrations were verified by plating the cells to determine viable counts. Six mice from each group were then injected intraperitoneally with 0.1 mL of the cell suspension containing twice the 90-100% lethal dose (LD90-100); this inoculum of 4×103 cfu/mouse was known to be 100% lethal within 7 days (data not shown). Meanwhile, antibiotic doses were prepared in 0.85% sterile saline. At 1 hour post-inoculation, antibiotic or 0.85% sterile saline alone was administered as a single subcutaneous injection with a volume of 0.3 mL per dose. The mice were then monitored daily for 7 days to measure survival. The ED50 was defined as the single dose giving protection to 50% of the test mice.
1.9 Quantitative real-time PCR (qRT-PCR)
K. pneumoniae strains were cultured in Mueller-Hinton broth (MHB) at 37° C. overnight, diluted (1:100) in fresh MHB, and then incubated at 37° C. until an OD600 of 0.8 (the mid-exponential growth phase) is reached. RNA was extracted using the RNeasy kit and treated with RNase-free DNase I according to the manufacturer's instructions (Qiagen). RNA yield and quality was measured using the NanoVue spectrophotometer (GE Healthcare Life Sciences). cDNAs were synthesized from 1 μg of RNA template using the Omniscript Reverse Transcriptase according to the manufacturer's instructions (Qiagen). Relative quantification of gene expression was performed using ABI PRISM 7900HT real-time PCR System (Applied Biosystems) with the Maxima SYBR Green qPCR Master Mix (Thermo Scientific) and primers listed in Table 5. Fold-change values were calculated after normalization of each gene to the 23S rRNA internal control,3 using the comparative threshold method with the NVT1001 strain as the reference strain.
2. Results
2.1 K. pneumoniae NVT1001
2.1.1 Porin Loss and Efflux-Pump Overexpression in Antibiotic Resistance
The MICs of antibiotics against chromosome-mediated resistance mechanisms, namely, OmpK35/36 loss and AcrAB-TolC overexpression (ΔramR), are shown in Table 6. These results demonstrate that OmpK35/36 loss is related to increased resistance to β-lactams, folate pathway inhibitors, fosfomycins and nitrofurans, whereas AcrAB-To1C overexpression (ΔramR) is associated with increased resistance to β-lactams, quinolones, tetracyclines, folate pathway inhibitors, phenicols and nitrofurans. The two resistance mechanisms alone or in combination had no significant (≥4-fold) effects on the MIC(s) of imipenem, aminoglycosides or polymyxins. The results shown above were further validated by testing the antimicrobial susceptibility of the revertant strains, and similar results were found when comparing the MIC of the wild-type strain NVT1001 or its mutant to the MIC of the revertant with the same genotype (Table 7).
0.25
0.5
0.5
0.5
1
1
32
32
32
32
16
16
16
256
64
64
>256
>256
16
32
32
64
>256
128
16
128
64
64
>256
>256
1
2
2
2
2
0.25
2
1
1
4
4
1
0.5
0.5
4
2
1
1
1
4
4
2
0.125
0.125
4
4
0.5
2
2
0.25
0.5
32
64
32
32
0.5
0.5
0.5
0.5
2
2
2
2
2
2
2
2
1
1
1
1
1
1
1
1
32
32
32
64
64
64
64
128
64
128
128
128
8
8
8
8
8
8
16
>32
>1024
>1024
>1024
>1024
>1024
>1024
1
8
128
128
128
128
512
512
>1024
>512
>512
256
256
>512
>512
aTZB, tazobactam with a fixed concentration of 4 mg/L; CLA, clavulanic acid with a fixed concentration of 2 mg/L; SXT, trimethoprim/sulfamethoxazole (only the trimethoprim portion of the 1/19 drug ratio is displayed).
bBoldface numbers indicate a significant (≥4-fold) difference in the MICs of the NVT1001 strain and its mutants.
cWT, NVT1001; Δ35, ΔompK35 mutant; Δ36, ΔompK36 mutant; Δ35/36, ΔompK35/36 mutant; ΔramR, ΔramR mutant; ΔramRΔ35, ΔramRΔompK35 mutant; ΔramRΔ36, ΔramRΔompK36 mutant; ΔramRΔ35/36, ΔramRΔompK35/36 mutant.
0.25
0.5
0.5
0.5
1
1
32
32
32
32
16
16
16
16
32
>256
64
128
>256
>256
16
32
32
32
>256
128
16
64
64
64
>256
>256
1
1
2
2
2
2
0.25
2
1
1
4
4
1
0.5
0.5
2
2
1
1
1
4
4
1
0.125
0.125
4
4
0.5
2
2
0.25
0.25
0.5
64
64
32
32
0.25
0.25
0.5
0.5
2
2
2
2
2
2
2
2
0.5
0.5
1
1
0.5
0.5
1
1
32
32
32
64
64
64
64
128
128
128
128
128
8
8
8
8
8
8
8
>32
>1024
>1024
>1024
>1024
>1024
>1024
1
8
64
64
128
128
512
512
>1024
>512
>512
256
256
>512
>512
aTZB, tazobactam with a fixed concentration of 4 mg/L; CLA, clavulanic acid with a fixed concentration of 2 mg/L; SXT, trimethoprim/sulfamethoxazole (only the trimethoprim portion of the 1/19 drug ratio is displayed).
bBoldface numbers indicate a significant (≥4-fold) difference in the MICs of the NVT1001 strain and its derived strains.
cΔramRΔ35/36::ramR::35/36, ΔramRΔompK35/36::ramR::ompK35/36 revertant; ΔramRΔ35/36::ramR::36, ΔramRΔompK35/36::ramR::ompK36 revertant; ΔramRΔ35/36::ramR::35, ΔramRΔompK35/36::ramR::ompK35 revertant; ΔramRΔ35/36::ramR, ΔramRΔompK35/36::ramR revertant; ΔramRΔ35/36::35/36, ΔramRΔompK35/36::ompK35/36 revertant; ΔramRΔ35/36::36, ΔramRΔompK35/36::ompK36 revertant; ΔramRΔ35/36::35, ΔramRΔompK35/36::ompK35 revertant; ΔramR435/36, ΔramRΔompK35/36 mutant.
2.1.2 β-Lactams
The MICs of β-lactams against associated resistance mechanisms are shown in Tables 8 and 9. In particular, the MICs for extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases are shown in Table 8, while those for carbapenemases are shown in Table 9. The production of ESBLs when tested alone showed no significant (≥4-fold) effects on the MIC of piperacillin/tazobactam, cefoxitin, imipenem or doripenem, and the production of AmpC β-lactamases when tested alone showed no significant (≥4-fold) effects on the MIC of imipenem (Table 8). With or without ESBLs or AmpC β-lactamases, the strains with AcrAB-TolC overexpression (ΔramR) all showed no significant (≥4-fold) effects on the MIC of imipenem or doripenem (Table 8). The production of KPC-2 or KPC-3 alone could confer intermediate resistance to cefoxitin as well as resistance to the other tested β-lactams (Table 9). In addition, with or without OmpK35/36 loss and/or AcrAB-TolC overexpression (ΔramR), the IMP-8, NDM-1, VIM-1 and OXA-48 strains were susceptible to aztreonam (Table 9).
0.25
0.5
0.5
0.5
1
1
32
32
32
32
16
16
16
256
64
64
>256
>256
16
32
32
64
>256
128
16
128
64
64
>256
>256
1
2
2
2
2
0.25
2
1
1
4
4
1
0.5
0.5
4
2
1
1
1
4
4
2
0.125
0.125
4
4
0.5
2
2
0.25
0.5
2
16
2
32
16
16
16
32
16
32
32
32
64
32
64
64
>256
64
64
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
16
64
64
64
>256
>256
1
4
2
8
8
8
8
16
64
128
>256
>256
128
128
>256
>256
8
16
16
128
16
16
256
256
128
>256
>256
>256
>256
>256
>256
>256
0.125
0.25
0.25
8
0.25
0.25
16
16
2
2
2
1
0.5
0.5
256
>256
>256
>256
>256
>256
>256
>256
>256
64
64
>256
>256
32
128
64
>256
128
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
16
64
64
64
>256
>256
64
>256
64
>256
256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
64
>256
>256
>256
256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
0.5
0.5
0.5
>32
0.5
0.5
>32
>32
4
2
2
0.25
0.25
0.25
8
0.25
0.25
4
4
0.25
4
2
2
128
>256
128
>256
>256
>256
>256
>256
>256
64
32
>256
>256
32
128
64
>256
256
256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
64
64
128
>256
256
128
>256
>256
16
128
64
64
>256
>256
64
>256
128
>256
>256
>256
>256
>256
32
32
32
>256
64
64
256
256
4
4
4
128
8
8
64
128
16
16
16
64
16
16
32
32
0.06
0.06
0.06
4
0.125
0.125
4
4
1
1
2
1
0.5
0.5
64
128
64
256
64
64
64
64
>256
>256
>256
>256
256
256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
256
256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
64
128
>256
>256
128
128
>256
>256
2
2
16
32
4
4
16
16
64
64
256
>256
64
64
256
128
1
1
4
>32
1
1
>32
>32
4
>32
32
32
0.25
0.25
2
16
0.25
0.25
8
8
0.25
0.25
1
8
4
4
1
8
1
16
4
4
8
8
>256
32
32
64
64
256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
16
128
32
>256
64
64
64
128
8
16
16
64
16
16
64
64
0.25
0.25
1
0.5
0.5
4
4
8
8
8
16
8
8
16
16
1
1
1
>32
1
1
>32
>32
32
16
16
0.25
0.25
0.25
8
0.25
8
4
0.25
8
4
4
aNo, no supplemental plasmid. The β-lactamase on the low-copy-number plasmid pACYC177 is shown, and the plasmid was transferred into K. pneumoniae NVT1001 and its mutants. The DHA-1 was cloned with its regulator AmpR. TZB, tazobactam with a fixed concentration of 4 mg/L; CLA, clavulanic acid with a fixed concentration of 2 mg/L.
bBoldface numbers indicate a significant (≥4-fold) difference in the MICs of the NVT1001 strain and its derived strains, while no significant (≥4-fold) differences in the MICs of the NVT1001 with or without plasmid pACYC177 alone (data not shown).
CWT, NVT1001; Δ35, ΔompK35 mutant; Δ36, ΔompK36 mutant; Δ35/36, ΔompK35/36 mutant; ΔramR, ΔramR mutant; ΔramRΔ35, ΔramRΔompK35 mutant; ΔramRΔ36, ΔramRΔompK36 mutant; ΔramRΔ35/36, ΔramRΔompK35/36 mutant.
0.25
0.5
0.5
0.5
1
1
32
32
32
32
16
16
16
256
64
64
>256
>256
16
32
32
64
>256
128
16
128
64
64
>256
>256
1
2
2
2
2
0.25
2
1
1
4
4
1
0.5
0.5
4
2
1
1
1
4
4
2
0.125
0.125
4
4
0.5
2
2
0.25
0.5
>256
>256
256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
16
32
64
>256
128
128
>256
>256
16
64
32
256
128
128
128
128
128
256
256
>256
256
256
>256
>256
64
64
64
>256
64
64
>256
>256
256
>256
>256
>256
>256
>256
>256
>256
32
32
32
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
32
>32
>32
>32
32
>32
>32
>32
16
32
>32
>32
16
32
>32
>32
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
16
32
64
>256
128
128
>256
>256
128
>256
128
>256
>256
>256
>256
>256
128
256
256
>256
256
256
>256
>256
128
128
256
>256
128
128
>256
>256
256
256
>256
>256
256
256
>256
>256
32
32
32
>32
32
32
>32
>32
32
>32
>32
>32
32
32
>32
>32
16
32
>32
>32
32
>32
>32
>32
8
32
>32
>32
16
32
>32
>32
0.25
0.5
0.5
0.5
0.5
0.5
16
16
16
64
32
64
64
64
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
64
128
256
>256
128
128
256
256
16
32
64
>256
32
64
128
128
64
64
64
>256
32
64
64
128
2
4
2
>32
4
4
>32
>32
4
4
8
>32
4
4
>32
>32
2
1
2
>32
2
2
>32
>32
1
2
2
>32
1
2
32
32
0.25
0.5
0.5
0.5
0.5
0.5
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
256
256
>256
>256
>256
>256
>256
>256
32
128
>256
>256
>256
256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
32
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
32
32
>32
>32
32
32
>32
>32
16
32
>32
>32
32
32
>32
>32
0.25
0.5
0.5
0.5
1
1
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
128
256
>256
>256
>256
>256
>256
>256
256
>256
>256
>256
>256
>256
>256
>256
2
4
2
>32
4
4
>32
>32
16
32
>32
>32
16
16
>32
>32
16
>32
>32
>32
>32
32
>32
>32
16
32
>32
>32
32
32
>32
>32
0.25
0.125
0.5
0.5
0.5
0.5
0.5
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
256
256
>256
>256
>256
>256
>256
>256
16
32
128
64
64
>256
>256
16
128
128
64
>256
>256
1
2
2
2
2
2
2
4
16
32
4
4
32
32
0.5
1
1
8
1
1
8
8
8
8
8
32
8
8
8
16
4
8
8
>32
8
8
>32
>32
4
4
8
>32
4
4
>32
>32
2
2
8
>32
2
2
>32
>32
2
2
8
>32
2
1
>32
>32
aNo, no supplemental plasmid. The carbapenemase on the low-copy-number plasmid pACYC177 is shown, and the plasmid was transferred into K. pneumoniae NVT1001 and its mutants. TZB, tazobactam with a fixed concentration of 4 mg/L; CLA, clavulanic acid with a fixed concentration of 2 mg/L.
bBoldface numbers indicate a significant (≥4-fold) difference in the MICs of the NVT1001 strain and its derived strains, while no significant (≥4-fold) differences in the MICs of the NVT1001 with or without plasmid pACYC177 alone (data not shown).
cWT, NVT1001; Δ35, ΔompK35 mutant; Δ36, ΔompK36 mutant; Δ35/36, ΔompK35/36 mutant; ΔramR, ΔramR mutant; ΔramRΔ35, ΔramRΔompK35 mutant; ΔramRΔ36, ΔramRΔompK36 mutant; ΔramRΔ35/36, ΔramRAΔompK35/36 mutant.
2.1.3 Quinolones
The MICs of quinolones against chromosome-mediated resistance mechanisms are shown in Table 10. Strains with a single mutation at GyrA (S83I, S83L, S83F, S83Y or D87N) or with AcrAB-TolC overexpression (ΔramR) showed significant (≥4-fold) increases in the MICs of all quinolones tested (Table 5). In contrast, the single mutation at ParC (S80I) showed no significant (≥4-fold) effects on the MIC of any of the quinolones tested, whereas significant (≥4-fold) increases in the MICs of quinolones were observed for the S83I, S83L, S83F, S83Y, S83I/D87N, S83L/D87N, S83F/D87N, S83Y/D87N and ΔramR/S83I mutants (Table 10). The results shown above were further validated by testing the antimicrobial susceptibility of the revertant strains, and similar results were found when comparing the MIC of the wild-type strain NVT1001 or its mutant to the MIC of the revertant with the same genotype (Table 11).
The MICs of quinolones against plasmid-mediated resistance mechanisms with or without combination with chromosome-mediated resistance mechanisms are shown in Table 6. In contrast to QnrB or QnrS, strains with AAC(6′)-Ib-cr exhibited a significant (≥4-fold) increase in the MIC of only ciprofloxacin or norfloxacin (Table 12). Even without plasmid-mediated resistance mechanisms, strains with the GyrA (S83I) mutation and AcrAB-TolC overexpression (ΔramR) could resist all tested quinolones (Table 12).
>256
0.5
2
2
0.5
1
>256
0.5
2
2
0.5
0.5
>256
0.5
2
2
0.5
0.5
>256
0.5
2
2
0.5
0.5
>256
0.25
2
1
0.5
0.5
32
0.5
2
2
1
1
>256
0.5
2
1
0.5
1
>256
0.5
2
2
1
1
>256
0.5
2
2
0.5
0.5
>256
0.5
2
2
0.5
0.5
>256
0.5
2
2
0.5
0.5
>256
4
16
4
2
8
>256
1
8
4
1
2
>256
0.5
8
2
0.5
1
>256
0.5
8
2
1
1
>256
32
64
32
8
>32
>256
32
64
32
8
32
>256
32
32
16
8
32
>256
16
32
16
4
32
>256
4
8
>32
16
8
>256
>32
128
>32
>32
>32
>256
>32
>256
>32
>32
>32
aBoldface numbers indicate a significant (≥4-fold) difference in the MICs of the NVT1001 strain and its mutants.
bNAL, nalidixic acid; CIP, ciprofloxacin; NOR, norfloxacin; OFX, ofloxacin; LVX, levofloxacin; MXF, moxifloxacin.
>256
0.5
2
2
1
1
>256
0.5
2
2
1
0.5
>256
0.5
2
2
0.5
0.5
>256
0.5
2
2
0.5
0.5
>256
0.25
1
1
0.5
0.5
32
0.25
2
2
1
1
>256
0.5
2
1
0.5
1
>256
0.5
2
2
1
1
>256
0.5
2
2
1
1
>256
0.5
2
2
0.5
1
>256
0.5
2
2
0.5
0.5
>256
4
16
8
4
4
>256
2
8
4
2
1
>256
1
4
4
1
0.5
>256
1
4
4
1
0.5
>256
32
64
32
8
>32
>256
32
64
32
8
32
>256
32
32
16
8
32
>256
16
32
16
4
32
>256
4
8
>32
8
8
>256
>32
128
>32
>32
>32
>256
>32
>256
>32
>32
>32
aBoldface numbers indicate a significant (≥4-fold) difference in the MICs of the NVT1001 strain and its derived strains.
bNAL, nalidixic acid; CIP, ciprofloxacin; NOR, norfloxacin; OFX, ofloxacin; LVX, levofloxacin; MXF, moxifloxacin.
K. pneumoniae NVT1001
>256
>256
>256
32
>256
>256
>256
0.5
4
32
0.5
4
>32
>32
2
16
64
2
8
128
>256
2
4
32
2
>32
>32
>32
0.5
2
8
1
16
>32
>32
1
8
>32
1
8
>32
>32
32
>256
>256
>256
256
>256
>256
>256
0.5
2
>32
>32
4
>32
>32
>32
2
8
>256
>256
16
64
>256
>256
4
8
>32
>32
32
>32
>32
>32
1
2
16
>32
8
>32
>32
>32
2
8
>32
>32
>32
>32
>32
>32
16
>256
>256
>256
64
>256
>256
>256
1
2
>32
>32
4
32
>32
>32
2
8
64
128
32
64
>256
>256
4
8
>32
>32
16
>32
>32
>32
1
4
32
>32
8
>32
>32
>32
1
8
>32
>32
>32
>32
>32
>32
>256
>256
>256
64
>256
>256
>256
2
16
>32
0.5
16
>32
>32
1
8
128
>256
8
128
>256
>256
4
8
32
2
>32
>32
>32
0.5
2
8
1
8
>32
>32
1
8
>32
1
16
>32
>32
aNo, no supplemental plasmid. The Qnr protein or the aminoglycoside modifying enzyme on the low-copy-number plasmid pACYC177 is shown, and the plasmid was transferred into K. pneumoniae NVT1001 and its mutants.
bBoldface numbers indicate a significant (≥4-fold) difference in the MICs of the NVT1001 strain and its derived strains, while no significant (≥4-fold) differences in the MICs of the NVT1001 with or without plasmid pACYC177 alone (data not shown).
cWT, NVT1001; S83I, S83I mutant; S83I/S80I, S83I/S80I mutant; S83I/D87N/S80I, S83I/D87N/S80I mutant; ΔramR, ΔramR mutant; ΔramR/S83I, ΔramR/S83I mutant; ΔramR/S83I/S80I, ΔramR/S83I/S80I mutant; ΔramR/S83I/D87N/S80I, ΔramR/S83I/D87N/S80I mutant.
2.1.4 Aminoglycosides
The MICs of aminoglycosides for each resistance mechanism are shown in Table 13. Several different resistance profiles were found among the strains with different aminoglycoside-modifying enzymes, though all were susceptible to amikacin (Table 13). The production of 16S rRNA methylase, ArmA and RmtB was not associated with observable effects on the MIC of spectinomycin or streptomycin, whereas both conferred strong resistance to all other aminoglycosides tested (Table 13).
32
4
32
8
64
>256
8
32
8
8
64
>256
64
>1024
16
>256
>256
1024
>256
>256
>256
>256
>256
>256
>256
>256
>256
>256
aNo, no supplemental plasmid. The aminoglycoside modifying enzyme or 16S rRNA methylases on the low-copy-number plasmid pACYC184 is shown, and the plasmid was transferred into K. pneumoniae NVT1001.
bBoldface numbers indicate a significant (≥4-fold) difference in the MICs of the NVT1001 strain and its derived strains, while no significant (≥4-fold) differences in the MICs of the NVT1001 with or without plasmid pACYC184 alone (data not shown).
cAMK, amikacin; GEN, gentamicin; KAN, kanamycin; NET, netilmicin; SPT, spectinomycin; STR, streptomycin; TOB, tobramycin.
2.1.5 Tetracyclines
The MICs of tetracyclines for various resistance mechanisms are shown in Table 14. With or without AcrAB-To1C overexpression (ΔramR), the production of Tet(B), Tet(C), Tet(D), or Tet(M) showed no observable effects on the MIC of tigecycline (Table 8). AcrAB-TolC overexpression (ΔramR) and Tet(A) production both conferred an 8-fold increase in the MIC of tigecycline, and a 32-fold increase was found when the two mechanisms were combined (Table 14).
>256
>256
16
>256
16
>256
>256
16
128
32
32
32
4
128
32
8
32
>256
>256
256
>256
128
64
>256
>256
128
256
128
64
>256
>256
64
>256
>256
8
32
8
8
8
8
aBoldface numbers indicate a significant (≥4-fold) difference in the MICs of the NVT1001 strain and its derived strains, while no significant (≥4-fold) differences in the MICs of the NVT1001 with or without plasmid pACYC177 alone (data not shown).
bNo, no supplemental plasmid. The tet resistance gene on the low-copy-number plasmid pACYC177 is shown, and the plasmid was transferred into K. pneumoniae NVT1001.
2.1.6 Folate Pathway Inhibitors
The MICs of folate pathway inhibitors against associated resistance mechanisms are shown in Table15. Strains with single resistance mechanisms were all susceptible (≤2/38 mg/L) to trimethoprim/sulfamethoxazole, and strains with certain combinations of mechanisms became resistant to trimethoprim/sulfamethoxazole (Table 15). Strains with porin loss and/or Sul production all showed no significant (≥4-fold) effects on the MIC of trimethoprim, whereas most of the other strains with combined mechanisms were associated with significant (≥4-fold) increases in the MICs of all folate pathway inhibitors tested (Table 15).
K. pneumoniae NVT1001
8
8
16
>32
>1024
>1024
>1024
>1024
>1024
>1024
1
8
16
32
>32
>32
>1024
>1024
>1024
>1024
>1024
>1024
>1024
>1024
2
2
4
16
16
>32
>32
16
32
32
>32
>1024
>1024
>1024
>1024
>1024
>1024
>1024
>1024
1
2
2
2
8
8
16
>32
>32
>32
>32
>32
>32
>32
>32
>32
>1024
>1024
>1024
>1024
>1024
>1024
>1024
2
8
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
>32
>1024
>1024
>1024
>1024
>1024
>1024
>1024
1
4
8
16
4
4
>32
>32
aNo, no supplemental plasmid. The drug-resistant target enzyme on the low-copy-number plasmid pACYC177 is shown, and the plasmid was transferred into K. pneumoniae NVT1001. SXT, trimethoprim/sulfamethoxazole (only the trimethoprim portion of the 1/19 drug ratio is displayed).
bBoldface numbers indicate a significant (≥4-fold) difference in the MICs of the NVT1001 strain and its derived strains, while no significant (≥4-fold) differences in the MICs of the NVT1001 with or without plasmid pACYC177 alone (data not shown).
cWT, NVT1001; Δ35, ΔompK35 mutant; Δ36, ΔompK36 mutant; Δ35/36, ΔompK35/36 mutant; ΔramR, ΔramR mutant; ΔramRΔ35, ΔramRΔompK35 mutant; ΔramRΔ6, ΔramRΔompK36 mutant; ΔramRΔ35/36, ΔramRΔompK35/36 mutant.
2.1.7 In Vivo Investigation
To further demonstrate that this system can also be used to test the efficacy of antibiotics in vivo, a mouse infection model was used. The 50% effective doses (ED50 values) of ceftazidime and cefotaxime were specifically determined using K. pneumoniae NVT1001 harbouring the pACYC177 plasmid with blaOXA-48 (
2.2 A. baumannii KW1
2.2.1 Efflux Pump Overexpression
The single mutation in the regulator genes of AdeABC efflux pump could significantly (≥4-fold) increase the MICs of ceftazidime, gentamicin, tetracycline and/or tigecycline, including D20N, A91V or P116L mutation in AdeR and G30D, A94V, R152K or T153M mutation in AdeS (Table 16). These mutations could also confer a 2 or 3-fold increase in the MIC of ciprofloxacin (Table 16).
2.2.2 Quinolones Target Site Mutation
The single mutation S83L in GyrA could significantly (4-fold) increase the MICs of all quinolones tested (Table 17). With the further mutation in ParC, including G78C, S80L,
3
2
16
4
12
3
3
1.5
4
3
4
2
4
2
4
3
aBoldface numbers indicate a significant (≥4-fold) difference in the MICs of the KW1 strain and its mutants.
bCAZ, ceftazidime; CIP, ciprofloxacin; GM, gentamicin; TC, tetracycline; TGC, tigecycline.
S80W, S80Y or E84K mutation, could increase these MICs to high-level resistance (Table 17), whereas the single mutation of all these ParC mutations showed no significant (≥4-fold) effects on the MICs of any of the quinolones tested (Table 17).
>256
2
24
6
1
0.75
>256
32
>256
32
32
4
>256
>32
>256
>32
>32
6
>256
>32
>256
>32
>32
8
>256
>32
>256
>32
>32
6
>256
>32
>256
>32
>32
6
aBoldface numbers indicate a significant (≥4-fold) difference in the MICs of the KW1 strain and its mutants.
bNAL, nalidixic acid; CIP, ciprofloxacin; NOR, norfloxacin; OFX, ofloxacin; LVX, levofloxacin; MXF, moxifloxacin.
2.2.3 Plasmid-Mediated Resistance Mechanism of β-Lactams
The MICs of β-lactams against associated resistance mechanisms are shown in Table 18. The production of CTX-M-15 or ADC-30 could significantly (≥4-fold) increase the MICs of all β-lactams tested. The production of each carbapenemase tested all showed no increase effects on the MIC of aztreonam, and no increase effects on the MIC of ceftazidime could also be found on the production of OXA-type carbapenemases tested in this study.
>256
>256
>256
12
2
1.5
>256
>256
64
>256
>256
>32
3
4
48
>32
12
16
>256
>256
>32
>32
>32
>256
>256
>32
>32
>32
>256
>32
>32
>32
128
>32
6
6
64
>32
8
8
>256
>32
>32
>32
aNo, no supplemental plasmid. The extended-spectrum β-lactamase, AmpC β-lactamase or carbapenemase on the shuttle vector pYMAb5 is shown, and the plasmid was transferred into A. baumannii KW1.
bBoldface numbers indicate a significant (≥4-fold) difference in the MICs of the KW1 strain and its derived strains.
cATM, aztreonam; PP, piperacillin; PTc, piperacillin- tazobactam, tazobactam with a fixed concentration of 4 μg/ml; CAZ, ceftazidime; ETP, ertapenem; IP, imipenem; MP, meropenem; DOR, doripenem.
2.2.4 Plasmid-Mediated Resistance Mechanism of Aminoglycosides
The MICs of aminoglycosides for each resistance mechanism are shown in Table 19. Different resistance effects could be found on the production of these aminoglycoside-modifying enzymes, whereas all showed no increase effects on the MICs of amikacin, netilmicin and streptomycin. The production of 16S rRNA methylase, ArmA, was not associated with increase effects on the MICs of spectinomycin and streptomycin, whereas conferred strong resistance to all other aminoglycosides tested.
3
3
2
192
16
16
>256
>256
>256
>256
>256
aNo, no supplemental plasmid. The aminoglycoside modifying enzyme or 16S rRNA methylase on the shuttle vector pYMAb5Tc is shown, and the plasmid was transferred into A. baumannii KW1.
bBoldface numbers indicate a significant (≥4-fold) difference in the MICs of the KW1 strain and its derived strains.
cAMK, amikacin; GEN, gentamicin; KAN, kanamycin; NET, netilmicin; SPT, spectinomycin; STR, streptomycin; TOB, tobramycin.
2.2.5 Plasmid-Mediated Resistance Mechanism of Tetracyclines
The MICs of tetracyclines for its resistance mechanisms are shown in Table 20. The production of Tet(A), Tet(B) or Tet(C) could significantly (4-fold) increase the MICs of tetracycline, doxycycline and minocycline. In the MICs of tigecycline, the production of Tet(B) or Tet(M) showed no observable effects, whereas the production of Tet(A) could confer a 2 to 3-fold increase.
128
12
1.5
>256
32
1.5
48
192
2
aNo, no supplemental plasmid. The tet resistance genes on the shuttle vector pYMAb5 is shown, and the plasmid was transferred into A. baumannii KW1.
bBoldface numbers indicate a significant (≥4-fold) difference in the MICs of the KW1 strain and its derived strains.
cTC, tetracycline; DC, doxycycline; MC, Minocycline; TGC, tigecycline.
3. Discussion
In this study, 193 genetically engineered strains with different resistance mechanisms were constructed from K. pneumoniae NVT1001, a fully susceptible clinical isolate, including 29 strains with chromosome-mediated resistance, 33 strains with plasmid-mediated resistance and 131 strains with a combination of the two resistance mechanisms. In addition, 37 genetically engineered strains with different resistance mechanisms were constructed from A. baumannii KW1, a fully susceptible clinical isolate, including 18 strains with chromosome-mediated resistance and 19 strains with plasmid-mediated resistance. Because the resistance mechanisms of these strains were constructed, all are known to be resistant to specific antibiotics. In addition, the plasmid-mediated resistance mechanisms were constructed using non-conjugative plasmids without transposons, so these mechanisms are not easy to spread. These features suggest that using these strains is safer than using drug-resistant clinical isolates.
Also in contrast to clinical drug-resistant isolates, these genetically engineered strains have clear and simple antibiotic resistance mechanisms. In in vitro MIC assays, the resistance profiles of these strains were confirmed by testing the MICs against several well-known antibiotics. Investigators can estimate the effectiveness of their antibiotics by comparing their MIC results to those of well-known antibiotics. The MIC assay is usually the starting point for assessing antibiotics, and our results suggest that these strains were ready for testing antibiotic activities in vitro.
In vivo mouse infection models are commonly used to demonstrate the efficacy of antibiotics in protecting against lethal infection.28-30 Using a clinical K. pneumoniae isolate producing the carbapenemase OXA-48, a previous study found that the MIC of ceftazidime was 4-fold lower than that of cefotaxime and that the ED50 of ceftazidime was lower than that of cefotaxime.28 A similar result was obtained in the present study using K. pneumoniae NVT1001 harbouring the pACYC177 plasmid with blaOXA-48. In contrast to many other clinical isolates, this genetically engineered strain can effectively infect BALB/c mice without weakening their immune system, and its 100% lethal dose (LD100) is 4×103 cfu in the mouse infection model, similar to its parental strain NVT1001 (data not shown). Obtained without changing the immune system of mice, the in vivo results should be closer to the true antibiotic efficacy during clinical use. The results thus suggest that these genetically engineered strains are adequate for testing antibiotic activities in vivo.
For the development of antibiotics in the face of multidrug resistance, in vitro selection and earlier evaluation are important steps before in vivo studies and further clinical evaluation. In contrast to the use of clinical isolates, the use of the platform technology described here to evaluate antibiotics may elucidate the exact reason for and the level of resistance both in vitro and in vivo. This information may in turn help in estimation of the efficacy of and potential resistance to antibiotics. The modification of antibiotics' chemical structure and discontinuities in development can lower the costs associated with the development process. Furthermore, the global prevalence and distribution of antibiotic resistance genes are already available from various studies and monitoring groups.31-36 In combination with these data, the data obtained from this platform technology may also help in estimation of the rates of resistance to newly developed drugs across regions. Additionally, antibiotics should be used more carefully in regions where specific resistance mechanisms are epidemic.
The set of resistant strains included in this platform technology can be expanded. Specifically, through genetic construction, other resistance mechanisms or different combinations of mechanisms can also be constructed in the same parental strain, including newly identified mechanisms. Given that the genetic background of several important bacterial pathogens with high resistance rates is quite different from that of K. pneumoniae, specific resistance genes can be found in these pathogens.37′ 38 For example, the overexpression of the AdeABC efflux pump can confer antibiotic resistance in A. baumannii, whereas this efflux pump does not exist in K. pneumoniae.37 To completely evaluate the activities of antibiotics, these specific resistance mechanisms should also be constructed in their original pathogens; in fact, several of them have been successfully constructed by our group (data not shown).
In summary, various chromosomal and plasmid resistance mechanisms were constructed in this study, and especially mechanisms conferring resistance to β-lactams, quinolones, aminoglycosides, tetracyclines or folate pathway inhibitors, in fully susceptible bacterial strains. Our results demonstrate that this platform technology can be used to efficiently and effectively evaluate antibiotics targeting specific resistance mechanisms both in vitro and in vivo. The system can also be used to screen new antibiotics against multidrug-resistant bacteria.
This application claims priority to U.S. Provisional Application No. 62/463,168, filed on Feb. 24, 2017, the content of which is hereby incorporated by reference in its entirety.
| Number | Date | Country | |
|---|---|---|---|
| 62463168 | Feb 2017 | US |
